1. A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients. Issue 2 (4th September 2018) Authors: Netterberg, Ida; Li, Chi‐Chung; Molinero, Luciana; Budha, Nageshwar; Sukumaran, Siddharth; Stroh, Mark; Jonsson, E. Niclas; Friberg, Lena E. Journal: Clinical pharmacology & therapeutics Issue: Volume 105:Issue 2(2019) Page Start: 486 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. Issue 7 (23rd July 2021) Authors: Sanborn, Rachel E; Hamid, Omid; de Vries, Elisabeth GE; Ott, Patrick A; Garcia-Corbacho, Javier; Boni, Valentina; Bendell, Johanna; Autio, Karen A; Cho, Daniel C; Plummer, Ruth; Stroh, Mark; Lu, Lawrence; Thistlethwaite, Fiona Journal: Journal for immunotherapy of cancer Issue: Volume 9:Issue 7(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. Issue 7 (23rd July 2021) Authors: Naing, Aung; Thistlethwaite, Fiona; De Vries, Elisabeth G.E.; Eskens, Ferry A.L.M.; Uboha, Nataliya; Ott, Patrick A.; LoRusso, Patricia; Garcia-Corbacho, Javier; Boni, Valentina; Bendell, Johanna; Autio, Karen A.; Randhawa, Manreet; Durm, Greg; Gil-Martin, Marta; Stroh, Mark; Hannah, Alison L.; A... Journal: Journal for immunotherapy of cancer Issue: Volume 9:Issue 7(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Designing In and Around Tolerability Considerations for Immunotherapy Combinations. Issue 4 (11th December 2017) Authors: Stroh, Mark Journal: Clinical pharmacology & therapeutics Issue: Volume 103:Issue 4(2018) Page Start: 558 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: Model prediction and clinical confirmation. (24th May 2014) Authors: Stroh, Mark; Talaty, Jennifer; Sandhu, Punam; McCrea, Jacqueline; Patnaik, Amita; Tolcher, Anthony; Palcza, John; Orford, Keith; Breidinger, Sheila; Narasimhan, Narayana; Panebianco, Deborah; Lush, Richard; Papadopoulos, Kyriakos P.; Wagner, John A.; Trucksis, Michele; Agrawal, Nancy Journal: Journal of clinical pharmacology Issue: Volume 54:Number 11(2014:Nov.) Page Start: 1256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Quantitative Systems Pharmacology Model of a Masked, Tumor‐Activated Antibody. (26th July 2019) Authors: Stroh, Mark; Sagert, Jason; Burke, John M.; Apgar, Joshua F.; Lin, Lin; Millard, Bjorn L.; Kavanaugh, W. Michael Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 8:Number 9(2019) Page Start: 676 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer. (10th October 2017) Authors: García‐Carbonero, Rocío; van Cutsem, Eric; Rivera, Fernando; Jassem, Jacek; Gore, Ira; Tebbutt, Niall; Braiteh, Fadi; Argiles, Guillem; Wainberg, Zev A.; Funke, Roel; Anderson, Maria; McCall, Bruce; Stroh, Mark; Wakshull, Eric; Hegde, Priti; Ye, Weilan; Chen, Daniel; Chang, Ilsung; Rhee, Ina; Hur... Journal: Oncologist Issue: Volume 22:Number 10(2017) Page Start: 1281 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer. (8th March 2017) Authors: García‐Carbonero, Rocío; van Cutsem, Eric; Rivera, Fernando; Jassem, Jacek; Gore, Ira; Tebbutt, Niall; Braiteh, Fadi; Argiles, Guillem; Wainberg, Zev A.; Funke, Roel; Anderson, Maria; McCall, Bruce; Stroh, Mark; Wakshull, Eric; Hegde, Priti; Ye, Weilan; Chen, Daniel; Chang, Ilsung; Rhee, Ina; Hur... Journal: Oncologist Issue: Volume 22:Number 4(2017) Page Start: 375 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer. (April 2017) Authors: García‐Carbonero, Rocío; van Cutsem, Eric; Rivera, Fernando; Jassem, Jacek; Gore, Ira; Tebbutt, Niall; Braiteh, Fadi; Argiles, Guillem; Wainberg, Zev A.; Funke, Roel; Anderson, Maria; McCall, Bruce; Stroh, Mark; Wakshull, Eric; Hegde, Priti; Ye, Weilan; Chen, Daniel; Chang, Ilsung; Rhee, Ina; Hur... Journal: Oncologist Issue: Volume 22:Number 4(2017) Page Start: 375 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans. (29th April 2013) Authors: Gibson, Christopher R.; Lu, Ping; Maciolek, Cheri; Wudarski, Christen; Barter, Zoe; Rowland-Yeo, Karen; Stroh, Mark; Lai, Eseng; Nicoll-Griffith, Deborah A. Journal: Xenobiotica Issue: Volume 43:Number 12(2013:Dec.) Page Start: 1027 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗